Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$168 Mln
Revenue (TTM)
$53 Mln
Net Profit (TTM)
$-1 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.3
Industry P/E
--
EV/EBITDA
17.3
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$0.6
EPS
$-0.1
Face value
--
Shares outstanding
80,571,642
CFO
$-185.47 Mln
EBITDA
$-158.82 Mln
Net Profit
$-194.74 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
| 19.4 | -25.3 | 19.4 | -15.4 | 0.8 | -13.7 | -12.7 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
| -4.3 | 5.6 | 29.9 | 64.7 | -77.1 | 10.7 | 5.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
2.2 | 168.4 | 52.7 | -6.6 | -10.4 | -14.4 | -- | 3.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides... Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey. Address: 2 University Plaza, Hackensack, NJ, United States, 07601 Read more
President, CEO & Director
Mr. Dror Bashan
President, CEO & Director
Mr. Dror Bashan
Headquarters
Hackensack, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Protalix Biotherapeutics Inc (PLX) is $2.15 (NYSE) as of 02-Apr-2026 18:53 EDT. Protalix Biotherapeutics Inc (PLX) has given a return of 0.79% in the last 3 years.
Since, TTM earnings of Protalix Biotherapeutics Inc (PLX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-21.41
|
2.93
|
|
2024
|
51.97
|
3.53
|
|
2023
|
15.62
|
3.87
|
|
2022
|
-4.71
|
-6.61
|
|
2021
|
-1.37
|
-6.28
|
The 52-week high and low of Protalix Biotherapeutics Inc (PLX) are Rs 3.19 and Rs 1.32 as of 04-Apr-2026.
Protalix Biotherapeutics Inc (PLX) has a market capitalisation of $ 168 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Protalix Biotherapeutics Inc (PLX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.